A facial arteriovenous malformation (AVM) is an abnormal tangle of arteries and veins in the face where blood flows directly between them, bypassing the normal capillary network. Unlike hemangiomas, which are true tumors that typically appear in infancy and shrink on their own, facial AVMs are present from birth, grow with the person, and never spontaneously resolve. They are among the most challenging vascular anomalies to manage because they tend to worsen over time and sit in tissue that controls expression, breathing, eating, and appearance.
What Causes a Facial AVM
Facial AVMs are not inherited in the traditional sense. They arise from somatic genetic mutations, meaning the DNA change happens in a small cluster of cells during fetal development rather than being passed down from a parent. Research has identified the MAP2K1 gene as one of the most common culprits. In one study using whole-exome and whole-genome sequencing, somatic MAP2K1 mutations were found in the majority of extracranial AVM tissue samples tested, and mutant copies of the gene were concentrated in endothelial cells (the cells lining blood vessels) rather than in blood or saliva.1PubMed Central. Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation The mutations are missense changes or small deletions that increase the activity of a protein called MEK1, which sits in a signaling pathway that tells cells when to grow and divide. Several of these same mutations have been found in certain cancers, though AVMs themselves are not cancerous.
Subsequent work has expanded the genetic picture. A study that sequenced a larger set of extracranial AVM specimens found pathogenic variants not just in MAP2K1 but also in KRAS, BRAF, and RASA1, all of which participate in related growth-signaling pathways.2PubMed. Somatic mutational landscape of extracranial arteriovenous malformations and phenotypic correlations The practical upshot is that these mutations cause endothelial cells to misbehave, forming and maintaining abnormal vessel connections instead of orderly capillary beds. Because the mutations are somatic and confined to a patch of tissue, a person with a facial AVM does not have an elevated risk of passing the condition to their children.
What Triggers Growth and Worsening
Many facial AVMs sit quietly for years, sometimes mistaken for a birthmark or a faint blush of color on the skin. Three categories of triggers are widely recognized as catalysts for rapid expansion. Puberty and its associated hormonal surges can push a previously stable AVM into a more aggressive phase. Pregnancy carries a similar risk: the hemodynamic and hormonal changes of pregnancy can cause an AVM to enlarge and even rupture.3PubMed Central. Extracranial Arteriovenous Malformations Rupture in Pregnancy Trauma to the face, whether from an accident or a surgical procedure, is the third common trigger.4An International Journal of Otorhinolaryngology Clinics. Traumatic Arteriovenous Malformation of Cheek: A Case Report and Review of Literature
Once an AVM starts to expand, the progression tends to be relentless. A case series examining ten patients with extensive cervicofacial AVMs found that every single patient experienced progressive growth, worsening symptoms, and advancing disease stage over the course of many years, eventually presenting with massive lesions, bleeding, pain, and facial destruction.5PubMed. Clinical course of arteriovenous malformations of the head and neck: a case series This relentless natural history is why clinicians classify AVMs using the Schobinger staging system, which moves from Stage I (a quiescent, warm, pink lesion) through Stage II (enlargement with a palpable pulse or audible bruit), Stage III (pain, bleeding, ulceration, or tissue destruction), and finally Stage IV, where the AVM is so large and the arteriovenous shunting so severe that it strains the heart, a condition called high-output cardiac failure.6Interventional Radiology. Head and Neck Arteriovenous Malformations: Clinical Manifestations and Endovascular Treatments
How Facial AVMs Are Diagnosed
A suspected AVM in the face usually gets its first evaluation with MRI, which can show the extent of the lesion and distinguish it from other vascular anomalies such as venous malformations or lymphatic malformations. But conventional MRI alone sometimes underestimates how big the abnormal vessel network actually is. Time-resolved MR angiography (often called TRICKS-MRA) adds a dynamic view of blood flow, allowing clinicians to watch contrast move through the AVM in real time. One study comparing the two methods found that TRICKS-MRA identified more lesions larger than two centimeters than standard contrast-enhanced MRI did and was highly accurate at mapping the feeding arteries and draining veins, with over 93% overall accuracy when checked against surgical and angiographic findings.7The Egyptian Journal of Radiology and Nuclear Medicine. Facial vascular anomalies; MRI and TRICKS-MR angiography diagnostic approach
Catheter-based angiography remains the gold standard when detailed mapping of every feeding vessel is needed before treatment. During this procedure, a catheter is threaded through an artery and contrast dye is injected directly into the vessels supplying the AVM, producing a real-time roadmap. This level of detail is especially important in the face, where the internal and external carotid arteries supply overlapping territories and the consequences of blocking the wrong branch can include blindness or stroke.
Why Incomplete Treatment Makes Things Worse
One of the most counterintuitive facts about facial AVMs is that a half-measure is often worse than no treatment at all. Removing only part of the AVM, or tying off the main feeding artery without eliminating the malformation’s core (called the nidus), tends to stimulate aggressive regrowth. The remaining abnormal vessels recruit new blood supply, and the lesion comes back more complex and harder to treat than before.8PubMed Central. Management strategy for facial arteriovenous malformations This is why older surgical strategies, such as proximal ligation of the feeding vessel, have largely been abandoned. The goal with any intervention is to eliminate the nidus entirely, not just reduce flow through it.
Embolization and What It Can Accomplish
Embolization involves threading a catheter into the vessels feeding the AVM and injecting an agent that plugs them from the inside. Several agents are in use, and outcomes vary. A systematic review of head and neck AVM embolization found that the liquid adhesive n-butyl cyanoacrylate (NBCA, commonly called “glue”) achieved complete cure in about 88% of cases with zero reported complications. Onyx, a different embolic agent, achieved roughly 80% cure rates with a 14% complication rate. Ethanol had lower cure rates, around 52%, and a complication rate of about 33%.9PubMed Central. Embolization of arteriovenous malformations of head and neck: A systematic review
Onyx has some specific practical advantages in the face. A study evaluating its use for extracranial head and neck vascular anomalies found it effective at stopping acute bleeding in nearly all cases and, when used as a staged preoperative measure, allowed surgeons to resect the lesion afterward without significant blood loss. Side effects were mostly minor: temporary swelling, local tenderness, or numbness. There were no stuck catheters, vessel dissections, or vessel ruptures.10American Journal of Neuroradiology. Safety and Clinical Efficacy of Onyx for Embolization of Extracranial Head and Neck Vascular Anomalies
Despite these encouraging numbers, embolization alone rarely provides a lasting cure for facial AVMs. A retrospective study of 30 patients found that disease control was achieved in none of the cases treated with embolization alone. When embolization was followed by surgery, control rates jumped to about 78%, compared with roughly 69% for surgery alone.11PubMed. Long-term therapeutic outcomes of facial arteriovenous malformations: A retrospective bi-centric study of 30 cases This pattern shows up consistently in the literature: embolization is best understood as a powerful preparatory step rather than a standalone cure.
The Combined Approach and Its Timing
The current consensus favors super-selective embolization performed 24 to 48 hours before complete surgical resection.12PubMed Central. Management strategy for facial arteriovenous malformations The short interval matters: embolization reduces blood flow and makes the surgical field more manageable, but if too much time passes, collateral vessels begin to open up and the advantage is lost. A study of 13 patients treated with various strategies found that all nine who received the combined approach were free of recurrence after a mean follow-up of about two and a half years.13Journal of Cranio-Maxillo-Facial Surgery. Interdisciplinary treatment algorithm for facial high-flow arteriovenous malformations, and review of the literature
In practice, “complete resection” in the face is easier said than done. The AVM may involve the cheek, orbit, ear, lip, or scalp, intertwining with structures that the patient needs for normal life. Multidisciplinary teams typically include interventional radiologists, plastic surgeons, head and neck surgeons, and sometimes neurosurgeons, each contributing a piece of the treatment plan.
Protecting the Facial Nerve
The facial nerve runs through the parotid gland and fans out across the face, controlling the muscles of expression. Any surgery in the cheek, jaw, or temple region risks damaging it, which can leave the patient unable to close their eye, smile, or move their lip on the affected side. This is one of the most feared complications of facial AVM surgery, and specialized approaches have been developed to reduce the risk.
Intraoperative nerve monitoring, where electrodes placed in the facial muscles detect signals from the nerve in real time, allows the surgeon to identify and avoid branches during dissection. In a large series of over 200 vascular malformation surgeries using this technique, complete facial nerve trunk injury occurred in only about 1.5% of operations.14PubMed. New methodology for facial nerve monitoring in extracranial surgeries of vascular malformations A separate study that developed a tailored algorithm for AVMs specifically involving the facial nerve found no significant worsening of facial nerve function before versus after treatment, regardless of the type of nerve involvement or the reanimation procedure used.15Annals of Plastic Surgery. Treatment of Head and Neck Arteriovenous Malformations Involving the Facial Nerve: A Tailored Algorithm
Rebuilding the Face After Resection
When a facial AVM reaches Schobinger Stage IV with severe tissue destruction, removing it can leave behind a sizable defect. Bone, skin, muscle, and sometimes portions of the jaw or ear may be gone. Free-flap reconstruction, where tissue with its own blood supply is transplanted from another part of the body, is currently one of the preferred methods for filling these gaps.16PubMed. Clinical outcomes and recipient vessel selection for free flap transfer following arteriovenous malformation resection
A series of 16 patients with Stage IV facial AVMs treated with wide excision followed by free-flap transfer used anterolateral thigh flaps in most cases, along with rectus abdominis and radial forearm flaps for specific defects.17PubMed Central. Regulating Microvascular Free Flaps Reconstruction in “Schobinger Stage 4” Arteriovenous Malformations of Face The challenge is not just cosmetic: choosing the right recipient vessel to connect the flap to is unusually tricky because the surrounding vasculature has been distorted by years of abnormal flow. Surgeons have to carefully map which nearby arteries and veins are healthy enough to sustain the transplanted tissue.
Targeted Drug Therapies
The discovery that facial AVMs are driven by mutations in the RAS/MAPK and PI3K/mTOR signaling pathways has opened the door to medications originally developed for cancer. Sirolimus (also known as rapamycin), a drug that inhibits the mTOR pathway, has been used with encouraging early results in patients who are not good candidates for surgery or whose AVMs have recurred after previous interventions.18PubMed Central. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies
One illustrative case involved a 23-year-old woman with an AVM affecting her left orbit and face that caused pain, swelling, and difficulty opening her eye. She had declined surgery out of concern for cosmetic disfigurement and instead underwent palliative embolization followed by daily oral rapamycin. At six months, there was minimal residual flow into the AVM, and the swelling over her brow and eyelid had completely resolved.19PubMed Central. Medical Adjuvants in the Treatment of Surgically Refractory Arteriovenous Malformations of the Head and Face: Case Report and Review of Literature Case reports like this one are promising but not proof that the approach works broadly; controlled trials are still needed.
MEK inhibitors, which target the MAP2K1/MEK1 pathway more directly, are also under investigation. Because many facial AVMs carry activating mutations specifically in MAP2K1, these drugs have a clear molecular rationale. Clinical trials are ongoing, and the field is watching closely to see whether they can shrink AVMs or at least halt progression without the need for repeated procedures.
Emerging Procedural Techniques
A newer approach called bleomycin electrosclerotherapy (BEST) combines a chemotherapy drug, bleomycin, with electroporation, a technique that uses short electrical pulses to temporarily open pores in cell membranes so the drug can enter more effectively. Preliminary results in high-flow AVMs of the head showed measurable reductions in blood flow on ultrasound and good patient satisfaction.20PubMed Central. Innovative Use of Bleomycin Electrosclerotherapy (BEST) for High-Flow Arteriovenous Malformations in the Head District: Preliminary Results of Two Cases A related technique, modified electrosclerotherapy (MEST), has been used to achieve vascular control before surgical correction of AVMs with tissue overgrowth. The idea is that MEST reduces flow enough to make surgery safer and more complete, while surgery addresses the structural damage the AVM has already caused.21PubMed. Combined modified electro-sclero therapy (MEST) and surgical correction for arteriovenous malformations with tissue overgrowth Both approaches are in early stages of evaluation.
On the diagnostic side, researchers are exploring whether liquid biopsies, blood tests that detect fragments of mutant DNA shed by the AVM into the bloodstream, could eventually replace or reduce the need for tissue biopsies. Since the somatic mutations driving AVMs are confined to the malformation itself, finding circulating cell-free DNA carrying those mutations could theoretically allow clinicians to confirm the diagnosis, monitor treatment response, or detect recurrence with a simple blood draw.22PubMed Central. The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics This remains a conceptual framework for now, but it highlights the direction the field is heading.
Measuring Quality of Life
Living with a visible facial AVM affects far more than physical health. Pain, disfigurement, social stigma, and the burden of repeated procedures add up in ways that standard medical endpoints do not capture well. Researchers have developed specific questionnaires to measure these effects. Two validated tools, the PROVAM (Patient-Reported Outcome Measure for Vascular Malformation) and the OVAMA (Outcome Measures for Vascular Malformations), approach the problem from different angles. A prospective study comparing the two across 250 patient responses found that about two-thirds of respondents reported pain, and those patients tended to prefer the PROVAM questionnaire, which focuses more on functional impact. Patients with head and neck malformations who were not in pain tended to prefer OVAMA, which places more emphasis on physical symptoms and appearance.23PubMed. Comparison of the Patient-Reported Outcome Measure for Vascular Malformation and Outcome Measures for Vascular Malformation Questionnaires: A Prospective Cohort Study The OVAMA questionnaire has also been validated for its ability to detect changes over time, meaning it can track whether a treatment is making a real difference from the patient’s perspective.24British Journal of Dermatology. Responsiveness of the condition-specific Outcome measures for VAscular MAlformations (OVAMA) questionnaire to measure symptoms and appearance in patients with vascular malformations
These tools matter because treatment decisions for facial AVMs are rarely straightforward. A patient with a stable Stage I lesion that causes no symptoms might reasonably choose watchful waiting, while another patient at the same stage but with significant psychological distress over the appearance of the lesion might push for intervention. Having standardized ways to quantify a patient’s own experience gives both clinician and patient a shared language for weighing the risks of treatment against the costs of doing nothing.